Introduction
============

Autoimmune events have been reported in both pediatric and adult patients with chronic hepatitis B and C ([@b1-etm-0-0-8144]--[@b3-etm-0-0-8144]). Even though autoimmune hepatitis and viral hepatitis are completely different entities, both are secondary to disturbances of the immune system (hepatitis viruses B and C are poorly cytopathic) and its failure to properly adjust the immune reaction towards hepatocytes ([@b4-etm-0-0-8144],[@b5-etm-0-0-8144]).

Autoimmunity is defined as the loss of tolerance towards self-antigens, and its etiopathogenesis is still unknown. There are several factors considered to play a role in autoimmunity, such as genetic and environmental ones. Other factors, such as stress, are still being studied regarding their relationship with autoimmunity. Stress has been reported to be associated with onset and exacerbation of several autoimmune diseases. This is a new point of research, considering that stress has a major impact on modern lifestyle, and it is known to influence homeostasis and health ([@b6-etm-0-0-8144],[@b7-etm-0-0-8144]).

Persistence of hepatitis B or C viral infection depends on the interaction between the host\'s immune system and the virus. The destruction of the hepatocytes occurs when the immune reaction directed towards the hepatitis virus, essential for identifying the virus and subsequent viral clearance, generates an inflammatory reaction of the liver tissue through various mechanisms which up-regulate pro-inflammatory cytokines. Therefore, infected hepatocytes are destroyed by means of effector T cells. Concurrent, specific antibodies are generated by B cells in order to neutralize the virus. Previous research has shown that both viruses (hepatitis B virus and hepatitis C virus) possess the ability to escape the innate immune system, but a higher rate of persistence has been reported for the hepatitis C virus because it has the ability to escape the adaptive immunity as well. The adaptive immunity is responsible of recognizing antigenic structures and is sustained by B and T cells. One of its most important features is long-term memory, providing a quick secondary response. The ability of the hepatitis C virus to escape adaptive immunity resides in its high mutation rate ([@b5-etm-0-0-8144]).

Interferon treatment, which is widely used for treating chronic viral hepatitis, has also been incriminated in inducing autoimmunity ([@b3-etm-0-0-8144]). Interferon-based treatment is more advantageous than new therapies (nucleotide/nucleoside analogues) for chronic hepatitis B as it can provide immune-mediated control in many cases after only one year. Nucleotidic/nucleozidic analogues require long-term treatment courses and even though virological suppression is achieved in almost all patients, AgHBs clearance is low. Recently, a new strategy was approached by adding pegylated interferon in patients previously treated with nucleosidic/nucleotidic analogues in order to speed the clearance of AgHBs ([@b8-etm-0-0-8144]).

Children with chronic viral hepatitis B are often in an immune tolerant state, but there is not enough data on how or if they should be treated is this phase of the disease. An association of interferon and lamivudin was reported to improve the rates of undetectable viremia and 'e' seroconversion in these patients ([@b9-etm-0-0-8144]). Positive antinuclear antibodies, anti-smooth muscle antibodies, circulating immune complexes and rheumatoid factor were often reported in patients with chronic viral hepatitis B and C, but occurrence of autoimmune diseases did not appear to be correlated with the hepatitis B or C virus infection ([@b10-etm-0-0-8144]).

The present study assessed the autoimmune phenomena associated to pediatric chronic hepatitis B and C and whether the risk for autoimmune events is higher in patients who have received interferon treatment.

Patients and methods
====================

An observational prospective study was conducted, which included 114 pediatric patients previously diagnosed with chronic viral hepatitis, 92 patients with chronic hepatitis B and 22 with chronic hepatitis C. The patients presented to the Pediatrics Department of 'Grigore Alexandrescu' Emergency Children\'s Hospital in Bucharest, Romania, over a period of 40 months. Legal guardians of the patients signed an informed consent prior to inclusion in the study. The research was approved by the Ethics Committee of 'Grigore Alexandrescu' Emergency Children\'s Hospital - registration no. 8954/04.04.2018.

The subjects were divided in two groups - the first group included patients who had received treatment while the second group were treatment-naive. The patients who had been treated for chronic viral hepatitis were included in the study group at least 6 months after the medication was stopped (none of them was receiving treatment at the time of evaluation). The national treatment guide was followed: chronic viral hepatitis B patients were treated with α-2b interferon three times a week, while chronic viral hepatitis C patients were treated with pegylated-interferon once a week and daily ribavirin.

Several laboratory tests were performed for each patient. Autoimmune markers were pursued annually, including cryoglobulins, circulating immune complexes, complement abnormalities, rheumatoid factor and non-organ specific autoantibodies - antinuclear antibodies (ANA), anti-smooth muscle antibodies (ASMA), anti-liver kidney microsomal antibodies (LKM1).

Microsoft Excel was used to organize the data, while SPSS Kaplan-Meier survival curves were applied to evaluate the influence of treatment and period of time needed for the occurrence of the autoimmune phenomenon in these patients.

Results
=======

One hundred and fourteen patients were enrolled, all of them previously diagnosed with hepatitis B or C viral infection. The age of the patients ranged from 18 months to 18 years, mean age 9 years with a standard deviation of 4.9. In all patients we identified the mother to be chronically infected with hepatitis B or C virus, so we considered that the infection was transmitted vertically. Regarding gender, male to female ratio was 1.23.

No clinically overt autoimmune manifestations were identified, but serological evidence of autoimmunity was found in 50% of the patients at some point during follow-up. Forty-six percent of patients included in the study group had previously received treatment, of them 50% were subsequently identified with autoimmune phenomena. Fifty-four percent of the patients were treatment-naive, and 50% of them presented autoimmune manifestations.

Regarding the markers that defined the autoimmune phenomenon, 31 patients were defined by only one positive marker, 24 had two simultaneous positive autoimmune markers, and further 2 had three simultaneous positive markers. The markers that determined the autoimmune phenomenon are listed in [Table I](#tI-etm-0-0-8144){ref-type="table"}.

We found that the probability of identifying autoimmune manifestations increased the longer the patient was chronically infected. For patients who had received treatment the autoimmune markers were identified after a longer period of time when compared to the group who had not been treated. At \~190 months, in the treatment group the probability of the occurrence of an autoimmune event was \~65%, while at the same time in the non-treatment group all the patients presented with autoimmune phenomena ([Fig. 1](#f1-etm-0-0-8144){ref-type="fig"}).

The median for the time until the autoimmune manifestations occurred was 158 months in patients who had received treatment (with a 95% confidence interval between 123.27 and 192.72 months) and 71 months in treatment-naive patients (with a 95% confidence interval between 41.34 and 100.65 months) ([Table II](#tII-etm-0-0-8144){ref-type="table"}). The fact that there is no overlap between the confidence intervals for the two compared groups shows that the reported difference is clinically significant.

The identified difference was found to be statistically significant - log-rank (χ^2^ = 9.397, df = 1, P=0.002), Breslow (χ^2^ = 10.454, df = 1, P=0.001), Tarone-Ware (χ^2^ = 10.157, df = 1, P=0.001) ([Table III](#tIII-etm-0-0-8144){ref-type="table"}). The log-rank test tends to focus more on the significance of the difference of the curves later in time. The Breslow test tends to look at what happens to the curves earlier in the time course, while the Tarone-Ware tests focuses on what happens at the middle of the time course. We report a statistically significant difference between the two compared curves at each tested time ([Table III](#tIII-etm-0-0-8144){ref-type="table"}).

Discussion
==========

Previous studies have linked interferon treatment to the occurrence of autoimmune markers. A research study conducted in 2014 by Pop *et al* ([@b11-etm-0-0-8144]) showed that antinuclear antibodies occurred in 13.79% of the pediatric patients with chronic viral hepatitis B who had received interferon therapy and had previously tested negative. For patients who had not received treatment the incidence for antinuclear antibodies was only 2.56%. The difference was statistically significant (P=0.042). The same study states that the presence of these antibodies does not interfere with treatment response.

Other studies, which included adult patients, have shown that autoimmune markers were identified in 85% of the cases with chronic viral hepatitis C and 89% of the cases with chronic viral hepatitis B. The serologic autoimmune phenomenon was reported in 74% of patients who had received short-term treatment (\<30 weeks) vs. 85% of the patients with long-time treatment (\>50 weeks) ([@b10-etm-0-0-8144]). In our study, which included patients with both hepatitis B and hepatitis C, autoimmune markers were identified in 50% of the cases, less than reported in previous research conducted on adult subjects, possibly secondary to the shorter time of evolution in children. According to our study, patients with chronic viral infection who have not received treatment will most likely develop autoimmune serological phenomenon earlier when compared to those who received interferon-based therapy.

The autoimmune phenomenon in chronic viral hepatitis still carries a high degree of uncertainty, especially in the pediatric field. Long-term studies have concluded that patients with chronic viral hepatitis B who do not receive treatment developed an antibody titer similar to that of patients who have received interferon treatment, but after a longer period of time ([@b12-etm-0-0-8144]). This contradicts the results of the present study. Our results stand by the idea that even though interferon-based therapies may induce autoimmunity, viruses themselves are more likely to induce the appearance of autoimmune markers over time in patients who do not receive treatment.
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###### 

Autoimmune markers to determine the autoimmune phenomena.

                                                                     Patients (number and percent)   
  ------------------------------------------------------------------ ------------------------------- -------
  No autoimmune markers                                              57                              50
  Autoimmune phenomena                                               57                              50
  Positive markers                                                                                   
    Circulating immune complexes                                       5                             4.39
    Cryoglobulins                                                    10                              8.77
    Cryoglobulins, C4 complement fraction                              1                             0.88
    Cryoglobulins, circulating immune complexes                      4                               3.51
    ANA                                                                3                             2.63
    ANA, circulating immune complexes                                  2                             1.75
    Rheumatoid factor                                                12                              10.53
    Rheumatoid factor, circulating immune complexes                    3                             2.63
    Rheumatoid factor, cryoglobulins                                   8                             7.02
    Rheumatoid factor, cryoglobulins, circulating immune complexes     2                             1.75
    LKM1, C4 complement fraction                                       1                             0.88
    LKM1, ANA                                                          1                             0.88
    ASMA                                                               1                             0.88
    ASMA, circulating immune complexes                                 2                             1.75
    ASMA, cryoglobulins                                                2                             1.75
  Total number of patients                                           114                             100

###### 

Median time until the autoimmune manifestations occurred.

            Median for survival time                       
  --------- -------------------------- -------- ---------- ---------
  Yes       158,000                    17,717   123,275    192,725
  No          71,000                   15,131     41,343   100,657
  Overall   120,000                    18,107     84,510   155,490

###### 

Comparison between the two curves.

                                   Overall comparisons       
  -------------------------------- --------------------- --- -------
  Log-rank (Mantel-Cox)              9,397               1   0.002
  Breslow (Generalized Wilcoxon)   10,454                1   0.001
  Tarone-Ware                      10,157                1   0.001
